Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 8/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.37 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8949613 | 0.87 | LTB4R (0.51) | LTB4RTDP1SMN1; SMN2LTB4R2PTPN1 | |
| SCHEMBL8586606 | 0.81 | LTB4R (0.46) | LTB4RTDP1SMN1; SMN2 | |
| SCHEMBL8949587 | 0.80 | USP2 (0.49) | LTB4RTDP1SMN1; SMN2LTB4R2PTPN1 | |
| SCHEMBL8582900 | 0.80 | LTB4R (0.83) | LTB4RLTB4R2 | |
| SCHEMBL8957175 | 0.76 | LTB4R (0.61) | LTB4RSMN1; SMN2LTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL10987196 | 0.72 | CYSLTR2 (0.69) | LTB4RTDP1CYSLTR2CYSLTR1 | |
| SCHEMBL29213724 | 0.70 | TDP1 (0.54) | TDP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL5892324 | 0.69 | AR (0.48) | TDP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL10684105 | 0.69 | CYSLTR2 (0.55) | LTB4RTDP1LTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL8583488 | 0.69 | LTB4R (1.00) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0735870-A4 | USE OF PLA 2? INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | LILLY CO ELI (US) | 1998-08-19 | — | — | EP | disclosed |
| EP-0735870-A1 | USE OF PLA 2? INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5563164-A | TREATING ARTHRITIS, PSORIASIS, ASTHMA, INFLAMMATORY BOWEL DISEASE, OR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| US-5552441-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS AND RESPIRATORY SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| US-5478857-A | Administering inhibitor of phospholipase A2 | ELI LILLY AND COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
| WO-1995017183-A1 | USE OF PLA2 INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| US-5324743-A | Leukotriene B4 antagonists | ELI LILLY AND COMPANY (US) | 1994-06-28 | — | — | US | disclosed |